Of note, BTK inhibitor share a variety of clinical applications, ranging from treatment of B cell malignancies, to autoimmune diseases and COVID-19 (Zhu et al., 2021; Malekinejad et al., 2022; Rezaei et al., 2022; Weis et al., 2022), which raise the question on whether TBBPA may interfere with these therapeutic actions. The gene discussed is BTK; the disease is autoimmune disease.